TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

An update from Trinity Biotech ( ($TRIB) ) is now available. On August 12, 2025, Trinity Biotech announced breakthrough clinical trial results for ...

The company said its CGM+ system can deliver accurate readings across a 15-day lifespan, while also employing fewer ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

Trinity Biotech (Nasdaq:TRIB) today announced positive clinical trial results for its next-generation continuous glucose ...

Investing.com -- Trinity Biotech plc (NASDAQ: TRIB) stock rose 4.4% following the company’s announcement of positive clinical trial results for its next-generation continuous glucose monitoring (CGM) ...

Trinity Biotech (TRIB) announced clinical trial results demonstrating a major technical breakthrough and de-risking the commercial pathway for its ...

Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for ...

View the latest Trinity Biotech PLC ADR (TRIB) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Trinity Biotech plc recently unveiled CGM+, an AI-native, wearable biosensor that goes beyond traditional continuous glucose monitors and tracks glucose levels, cardiovascular activity and body ...

Trinity CineAsia has acquired European rights to $80M war epic Dongji Rescue (aka Dong Ji Island), inspired by the real story of the rescue by Chinese fisherman of British POWs from a WWII ...

Krystal Biotech's gene therapy Vyjuvek gains approval in Japan for treating dystrophic epidermolysis bullosa, expanding its global reach.